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We investigated the relationship between renal function, blood pressure variability (BPV), and nitric oxide (NO) in a group of
African Americans with normal or mildly impaired renal function. 24-hour ambulatory blood pressure monitoring was performed,
NO measured, and glomerular filtration rate (GFR) calculated in 38 African Americans. Participants were categorized as having
normal (GFR > 90 mL/min per 1.73 m2 ) or mildly impaired (GFR 60–89 mL/min per 1.73 m2 ) renal function. Diastolic BPV was
significantly lower in the mildly impaired renal function group. Regression analyses revealed a significant positive association
between GFR and diastolic BPV for the entire study group. Plasma NO levels were significantly higher in the mildly impaired renal
function group and negatively correlated with diastolic BPV. In conclusion, diastolic BPV was reduced in African Americans with
mildly impaired renal function, which may be the result of increased NO production. These results conflict with previous findings
in diseased and nonblack populations and could provide rationale for studying BPV early in the disease state when BP-buﬀering
mechanisms are still preserved.

1. Introduction
Blood pressure (BP) levels are the product of both environmental stimuli and internal regulatory mechanisms of the
cardiovascular and renal systems. As a result of the complex
interaction between extrinsic and intrinsic factors, BP undergoes continuous fluctuations over a 24-hour period. With
the development of noninvasive ambulatory BP monitoring,
blood pressure variability (BPV), a surrogate marker for
the complex interaction between external and internal
factors, can be quantified to assess the clinical importance
of daily fluctuations in BP. Cross-sectional studies have
reported that daytime and 24-hour BPV are both directly
associated with the prevalence and severity of target-organ
damage (TOD), independent of mean BP [1–4]. These
cross-sectional data have been confirmed by longitudinal

studies, as BPV has been identified as an independent
predictor of cardiovascular mortality [5, 6]. The association
between BPV and cardiovascular risk may be attributed to
the augmented mechanical stress placed on the vasculature
that occurs as a result of increased variability of blood
flow. The augmented mechanical stress may in turn facilitate
vascular remodeling and contribute to the advancement
in atherosclerosis, thereby conferring greater cardiovascular
risk.
In the renal vasculature, the augmented mechanical stress
characterized by greater BPV may lead to injury, activation,
and dysfunction of the glomerular endothelium. Therefore,
BPV may be a contributing factor in the progression of renal
disease by exerting a detrimental eﬀect on the glomerular
endothelium. Cross-sectional studies support a role for BPV
in renal dysfunction, as a direct association between BPV and
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renal damage, as indicated by microalbuminaria, has been
found [4, 7, 8]. Recently, it has been reported that the rate
of BPV, which accounts for both the magnitude of BPV
and the time elapsed between two successive BP readings
in quantifying how fast or slow BP values change, was a
significant predictor of impaired renal function in a large
cohort of adults with essential hypertension, suggestive that
the rate of BPV may also have clinical importance for
renal function [9]. Taken together, these results suggest that
both the magnitude and rate of BPV may contribute to
the accelerated progression of renal disease. However, the
association between BPV and renal function has not been
previously investigated in the early stages of renal disease
when BP-buﬀering mechanisms, including baroreceptor and
endothelial function, are still preserved. To better elucidate
this relationship and implicate BPV in the acceleration of
renal disease, studies in the early stages of renal disease are
needed.
The purpose of this study was to investigate the relationship between BPV and renal function in a group of
normotensive and pre-hypertensive African Americans with
normal or mildly impaired renal function. Because the
release of nitric oxide (NO) from the endothelium may serve
as a BP-buﬀering mechanism in response to fluctuations in
blood flow and shear stress [10], a secondary purpose of this
study was to assess the potential association between NO and
BPV in this cohort of African Americans.

2. Methods
2.1. Participants. Participants were recruited via mailed
brochures and local newspaper advertisements. Upon
response to either, the participants were contacted by telephone to assess their eligibility. Each participant gave
written informed consent following the explanation of study
protocols during their first laboratory visit. The protocol
was approved by the Temple University Institutional Review
Board.
African American men and women between the ages of
40 to 75 years of age who were sedentary (regular aerobic
exercise <2 day per week), nonsmoking, nonmorbidly obese
(BMI < 40 kg/m2 ), not on lipid-lowering medication, and
had no history of cardiovascular disease, diabetes, hypercholestermia, liver disease, renal disease, or lung disease
were initially enrolled in the study. Both pre-menopausal
and post-menopausal women were included in the study; all
post-menopausal women were not on hormone replacement
therapy. Participants on more than one anti-hypertensive
medication were excluded from the study.
2.2. Screening. To ensure the eligibility of all qualified
participants, three screening visits were completed prior
to inclusion in the study. Screening visit one consisted of
blood sampling and urinalysis following a 12-hour overnight
fast to assess blood chemistries and renal function. Any
individual who had total cholesterol >240 mg/dL or who
had fasting blood glucose >126 mg/dL were excluded from
the study. Glomerular Filtration Rate (GFR) was calculated
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using the four-variable Modification of Diet in Renal Disease
(MDRD) study equation specific to African Americans
[11]: GFR (mL/min per 1.73 m2 ) = 186 × (SCr)−1.154 ×
(Age)−0.203× (0.742 if female) × (1.21 if black), where SCr
represents serum creatinine. Any individual who exhibited
evidence of renal disease (GFR < 60 mL/min per 1.73 m2 )
was excluded from the study. Participants were categorized
as having normal (GFR > 90 mL/min per 1.73 m2 ) or mildly
impaired GFR (GFR 60–89 mL/min per 1.73 m2 ) according
to National Kidney Foundation criteria.
Screening visits two and three required all qualified participants to undergo a physician administered physical examination and echocardiogram bicycle stress test to confirm
that participants displayed no evidence of cardiovascular,
pulmonary, or other chronic diseases.
2.3. Dietary Stabilization. Participants who met all inclusion
criteria after screening underwent dietary stabilization for
6 weeks prior to testing. Any participant receiving antihypertensive monotherapy (n = 14) was tapered oﬀ of
their medication during this dietary stabilization period.
Participants were instructed by a Registered Dietician on
the American Heart Association (AHA) Dietary Guidelines
for Healthy American Adults, a diet formerly known as
the AHA step 1 diet. This diet consisted of ∼55% of total
daily calories from carbohydrates, 15% from protein, and
<30% from fat, with saturated fat ≤10% of total calories,
sodium ≤ 3-4 g/day, and cholesterol intake <300 mg/day.
Participants met with the dietician one time per week at
which time body weight and BP were recorded for each
visit. Participants were required to remain within 5% of their
study entry body weight for the duration of the study. In
addition, participants who exhibited BP consistently greater
than 159/99 mmHg during the stabilization period were
excluded from the study. Compliance to the prescribed diet
was monitored by completion of a 3-day food record at the
conclusion of dietary stabilization. All participants who were
in compliance with the diet underwent testing 1-2 weeks after
dietary stabilization.
2.4. Oﬃce BP Measurements. Oﬃce BP measurements were
made in accordance with JNC 7 guidelines on three separate
occasions. BP was measured using a mercury sphygmomanometer after 5 minutes of quite rest in a chair, with
feet on the floor and arm supported at heart level. An
appropriate-size cuﬀ was applied around the participant’s
nondominant arm and BP values were identified from the
first and fifth phase of Korotokoﬀ sounds. BP measurements
were performed in triplicate, 5 min apart, and the average of
the three values was used as the BP for the visit.
2.5. 24-Hour Ambulatory BP Monitoring and Urine Collection.
Participants underwent 24-hour ambulatory BP monitoring
(ABPM) using a non-invasive monitor (SpaceLabs Medical
Inc., Model 90219, Redmond, WA) beginning on the morning of each participant’s typical day, with the exclusion of
Friday through Sunday. The BP cuﬀ was fitted to the participant’s nondominant arm with cuﬀ size determined by upper
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2.6. Analysis of ABPM Data. Awake and sleep periods were
defined according to self-reported sleep times recorded
in participants’ diaries. 24-hour, awake, and sleep mean
values were calculated for systolic BP (SBP), diastolic BP
(DBP), mean arterial pressure (MAP), and heart rate (HR).
Participants were categorized as pre-hypertensive (120/80–
139/89) or normotensive (<120/80 mmHg) according to
their mean 24-hour BP. Any participants with mean 24-hour
BP >140/90 mmHg were excluded from analyses. ABPM
measurements were used instead of oﬃce BP measurements
under the assumption that BP measurements obtained
during ABPM reflect a participant’s BP in their natural
environment, outside the influence of experimental settings.
Because current criteria for ABPM do not have a clearly
defined pre-hypertensive category, we defined prehypertension according to JNC 7 guidelines (120/80–139/89 mmHg)
[12].
The % dip in BP during sleep was calculated as: (Awake
BP − Sleep BP) × (100/awake BP). BPV was calculated using
the average real variability (ARV) index [13]
ARV =

1

N
−1

N − 1 K =1

|BPk+1 − BPk |,

N −1

i=1 |ri |
,
N −1

(2)

where N is the number of valid BP measurements. ri is
defined as follows:
ri =

Si+1 − Si
,
ti+1 − ti

7.8

P < .05

P < .05

NS

24-hour

Awake

Sleep

7.3

6.8

6.3

5.8

Normal
Mildly impaired

Figure 1: Renal function group diﬀerences in DBP variability for
awake, sleep, and 24-hour periods.

at time index
tri =

ti + ti+1
,
2

(4)

Si and Si+1 represent two successive BP measurements at time
indices ti and ti+1 . We selected the rate of BP variation as an
additional measure of BPV because it accounts for the order
in which the BP measurements are obtained, as well as the
time between successive readings. Moreover, this parameter
permits the evaluation of how fast or slow and in which
direction BP values change. The rationale for using both the
ARV index and the rate of BP variation was to allow us to
quantify the absolute magnitude of BPV (ARV index), while
also considering the magnitude of BPV in relation to the
time that elapsed between successive BP readings (rate of BP
variation).

(1)

where N is the number of valid BP measurements and BPk+1
and BPk represent two successive BP measurements. The
rationale for selecting the ARV index for BPV calculations is
based on previous studies that have reported the ARV index
to be a more reliable representation of time series variability
than standard deviation or coeﬃcient of variation [13, 14].
The rate of BP variation was calculated according to the
formula described by Zakopoulos et al. [15]
R = |r | =

8.3

DBP variability (mmHg)

arm circumference. BP measurements were obtained at 30
minute intervals during the day (6:00 AM–10:00 PM) and 60
minute intervals at night (10:00 PM–6:00 AM). Participants
were instructed not to exercise prior to or during the 24hour BP monitoring period and to pause momentarily and
maintain their body position during each BP measurement.
Throughout the duration of the 24-hour recording period,
participants were required to maintain a diary in which they
recorded their activity and emotional status at the time of
each BP measurement. Only recordings of good technical
quality (>80% of valid BP measurements) were included in
final analyses.
24-hour urine collection occurred on the same day as
ABPM. Total volume of urine was measured and recorded;
thereafter, urine samples were sent to Quest Diagnostics for
measurement of urinary creatinine, urinary sodium (Na+ ),
and urinary albumin levels.

(3)

2.7. Bioelectrical Impedance Analysis (BIA). Body composition was assessed by whole-body BIA using the singlefrequency impedance instrument ImpediMed DF50 (San
Diego, CA). BIA was measured at 50 kHz on the right side
of the body, with two electrodes placed on each dorsal
right hand and dorsal right foot while participants were
lying in a supine position with their legs slightly apart and
hands resting next to the body palms down. Participants
were asked to remove all jewelry and other accessories prior
to measurements. All electrode sites were cleaned with an
alcohol swab before attachment. Measures were taken after
at least 10 min of lying in the supine position to reduce
possible errors from acute changes in body fluid distribution.
Three measurements were taken, and the mean output
values of impedance, phase, resistance, and reactance were
used for calculations of total fat mass and total lean body
mass according to the manufacturer’s standard operating
procedures.

4
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3. Results

Rate of DBP variation (mmHg/min)
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Figure 2: Renal function group diﬀerences in rate of DBP variation
for awake, sleep, and 24-hour periods.

2.8. Measurement of Plasma and Urinary Nitrates/Nitrites
(NOx). Blood samples were collected in the morning following a 12-hour overnight fast. Blood was drawn into K2 EDTA
tubes, centrifuged at 2000 g for 20 minutes at 4◦ C, and then
the plasma was frozen at −80◦ C until assay. On the day of
assay, plasma samples were ultrafiltrated through a 10,000
MWCO Amicon Ultra filter (Millipore) by microcentrifuge
at 14,000 g for 30 minutes at 4◦ C. Urine was aliquoted from
the total volume 24-hour urine collection and frozen at
−80◦ C until assay. All urine samples were diluted 1:10 in
Reaction Buﬀer (HEPES based). Levels of NO end-products
were measured using a modified Griess assay as previously
described [16]. Inter-assay and intra-assay CVs were 7.6%
and 10.6% respectively.
2.9. Statistical Analysis. Data are expressed as means ± the
standard error of the mean (SEM). The distribution of
all variables was examined using the Shapiro-Wilk test of
normality, and homogeneity of variances was determined
using Levene’s test. Variables that were found to fail the
normality test were log adjusted for any statistical analysis,
but true physiological values of any variable are reported
throughout the paper. Statistical comparisons were performed between normal and mildly impaired renal function
groups using the independent t-test. Diastolic BPV and the
rate of variation in DBP were also compared between the
two groups by ANCOVA after adjusting for age, gender,
BMI, plasma glucose, cholesterol values, and mean BP
levels obtained from oﬃce and ABPM measurements. The
relationship of each clinical, renal, and BP variable with GFR
and urinary albumin were tested using univariate and multivariate regression analyses. P values <.05 were considered
statistically significant for all analyses. All statistical analyses
were performed using SPSS version 17.0 (SPSS Inc., Chicago,
IL).

3.1. Clinical, Renal, and BP Characteristics of Normal and
Mildly Impaired Renal Function Groups. The final study
group consisted of 38 African American men (n = 5) and
women (n = 33) who were classified as having normal
(GFR > 90 mL/min per 1.73 m2 ; n = 22) or mildly impaired
renal function (GFR 60–89 mL/min per 1.73 m2 ; n = 16).
The clinical and renal characteristics of normal or mildly
impaired renal function groups are presented in Table 1.
All clinical and renal characteristics were similar between
the two groups with the exception of serum creatinine
and GFR. Mean BP levels obtained from oﬃce and ABPM
measurements are shown in Table 2. The normal renal
function group exhibited significantly higher oﬃce DBP
than the mildly impaired renal function group (P < .05).
Awake, sleep, and 24-hr SBP, DBP, MAP, and HR were similar
between the two groups.
3.2. BP Variability. Figure 1 displays the awake, sleep, and
24-hour diastolic BPV. The mildly impaired renal function
group exhibited significantly lower diastolic BPV during
the awake period even after adjusting for age, gender,
BMI, prior anti-hypertensive medication usage, and mean
BP levels from oﬃce and ABPM measurements. Similarly,
diastolic BPV was also significantly lower in the mildly
impaired renal function group during the 24-hour period.
This diﬀerence was significant after adjusting for gender and
BMI, but failed to reach significance after adjusting for age
and mean BP levels. There were no statistically significant
diﬀerences between the two groups for systolic BPV during
the awake (normal: 8.2 ± 0.4 versus mildly impaired: 8.4 ±
0.4 mmHg), sleep (normal: 8.7 ± 0.8 versus mildly impaired:
9.2 ± 0.8 mmHg), and 24-hour periods (normal: 8.4 ± 0.4
versus mildly impaired: 8.5 ± 0.4 mmHg). Likewise, MAP
variability (MAPV) was similar between the two groups
during the awake (normal: 7.5 ± 0.4 versus mildly impaired:
7.0 ± 0.3 mmHg), sleep (normal: 7.7 ± 0.8 versus mildly
impaired: 8.6 ± 1.4 mmHg), and 24-hour periods (normal:
7.6 ± 0.4 versus mildly impaired: 7.1 ± 0.2 mmHg).
3.3. Rate of BP Variation. The rate of variation in DBP
during the awake, sleep, and 24-hour periods are presented
in Figure 2. The rate of DBP variation was significantly
lower in the mildly impaired renal function group during
the awake and 24-hour periods. These diﬀerences remained
significant after adjusting for all clinical characteristics,
renal characteristics, and mean BP levels from oﬃce and
ABPM measurements. There were no statistically significant
diﬀerences between the two groups for the rate of variation in
SBP during the awake (normal: 0.258 ± 0.011 versus mildly
impaired: 0.269 ± 0.012 mmHg/min), sleep (normal: 0.146
± 0.014 versus mildly impaired: 0.158 ± 0.013 mmHg/min),
and 24-hour periods (normal: 0.237 ± 0.011 versus mildly
impaired: 0.246 ± 0.009 mmHg/min). Similarly, the rate
of variation in MAP was not statistically diﬀerent between
the two groups during the awake (normal: 0.237 ± 0.013
versus mildly impaired: 0.227 ± 0.011 mmHg/min), sleep
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Table 1: Clinical and renal characteristics of normal or mildly impaired renal function groups.

Variable
Clinical characteristics
#
Normotensive/pre-hypertensive
# Male/female
#
Med. taper/no Meds
Age (years)
BMI (kg/m2 )
Total fat free mass (kg)
Total fat mass (kg)
Total cholesterol (mg/dL)
LDL cholesterol (mg/dL)
HDL cholesterol (mg/dL)
Triglycerides (mg/dL)
Fasting glucose (mg/dL)
Renal characteristics
Urine total volume (mL)
Urinary Na+ (mmol/gCr)
Urinary creatinine (g/24hr)
Urinary albumin (mg/24hr)
Serum creatinine (mg/dL)
GFR (mL/min per 1.73 m2 )

Normal renal function
GFR > 90 mL/min per 1.73 m2 (n = 22)

Mildly impaired renal function
GFR 60–89 mL/min per 1.73 m2 (n = 16)

7/15 (32%/64%)
2/20 (9%/90%)
5/17 (23%/77%)
51.0 ± 1.4
33.0 ± 1.0
51.8 ± 1.4
38.9 ± 2.2
189.3 ± 6.1
111.1 ± 6.7
61.7 ± 3.8
82.3 ± 6.6
95.2 ± 2.1

7/9 (44%/56%)
3/13 (19%/81%)
9/7 (56%/46%)
54.1 ± 1.5
30.0 ± 1.3
51.1 ± 2.7
33.4 ± 2.9
202.6 ± 6.2
119.1 ± 6.5
66.0 ± 4.1
87.4 ± 8.1
94.5 ± 2.4

1708.8 ± 160.8
93.1 ± 7.6
1.5 ± 0.1
8.9 ± 0.8
0.8 ± 0.02
105.8 ± 2.1

1853.3 ± 267.6
91.8 ± 10.1
1.5 ± 0.1
8.2 ± 1.0
1.0 ± 0.03∗
78.6 ± 2.2∗

Values are expressed as means ± SEM. BMI, body mass index; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
∗ Denotes significant diﬀerence between groups; P < .05.

Table 2: Mean BP levels from oﬃce and ABPM measurements in normal and mildly impaired renal function groups.

Variable
Oﬃce BP
SBP (mmHg)
DBP (mmHg)
ABPM
24-hr SBP (mmHg)
24-hr DBP (mmHg)
24-hr MAP (mmHg)
24-hr HR (beats/min)
Awake SBP (mmHg)
Awake DBP (mmHg)
Awake MAP (mmHg)
Awake HR (beats/min)
Sleep SBP (mmHg)
Sleep DBP (mmHg)
Sleep MAP (mmHg)
Sleep HR (beats/min)
Dip SBP (%)
Dip DBP (%)

Normal renal function
GFR > 90 mL/min per 1.73 m2 (n = 22)

Mildly impaired renal function
GFR 60–89 mL/min per 1.73 m2 (n = 16)

127.3 ± 2.5
81.1 ± 1.7

122.7 ± 2.8
76.1 ± 2.9∗

127.1 ± 2.6
80.3 ± 1.9
96.5 ± 1.9
75.1 ± 2.4
128.5 ± 2.9
81.7 ± 1.9
97.8 ± 2.0
77.2 ± 2.5
117.0 ± 2.2
70.3 ± 1.9
86.7 ± 1.9
67.3 ± 2.7
8.8 ± 1.2
13.8 ± 1.5

126.4 ± 3.0
76.4 ± 2.3
93.7 ± 2.3
72.3 ± 2.1
129.0 ± 3.1
78.9 ± 2.5
96.3 ± 2.5
73.8 ± 2.3
116.1 ± 2.5
66.4 ± 1.9
83.4 ± 1.8
66.0 ± 2.2
9.8 ± 1.4
15.4 ± 2.3

Values are expressed as means ± SEM. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; GFR, glomerular
filtration rate; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.
∗ Denotes significant diﬀerence between groups; P < .05.
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Figure 3: Relationship between GFR and pNOx (a) and the uNOx/pNOx ratio (b).

(normal: 0.128 ± 0.016 versus mildly impaired: 0.149 ±
0.024 mmHg/min), and 24-hour periods (normal: 0.218 ±
0.011 versus mildly impaired: 0.208 ± 0.008 mmHg/min).
3.4. Regression Analyses. Univariate regression analyses of
selected clinical and ABPM variables predicting GFR in the
entire study group are presented in Table 3. Diastolic BPV
and MAPV during the awake and 24-hour periods, and the
rate of variation for DBP and MAP during the awake and
24-hour periods were identified as significant predictors of
GFR. Multivariate regression analyses predicting GFR in the
entire study group are presented in Table 4. A core regression
model was created using variables known to impact renal
function: age, BMI, 24-hour SBP, and 24-hour DBP. Each
variable identified as a significant predictor of GFR with
univariate analyses was then inserted separately into the
model. Awake diastolic BPV, 24-hour diastolic BPV, awake
rate of DBP variation, and 24-hour rate of DBP variation
all remained significant predictors of GFR after adjusting
for age, BMI, and mean 24-hour BP. To determine which
ABPM parameters were the strongest predictors of GFR,
all variables were entered into a forward step-wise linear
regression model. In the final model, only the 24-hour rate of
DBP variation was included as a predictor of GFR (β = .639,
P < .001), with 40.8% of the variation in GFR accounted for
by the final predictor model (r 2 = .408).
No associations were found for any BPV or BP variation parameter and urinary albumin in the entire study
group with univariate regression analyses. When the renal
function groups were analyzed separately, urinary albumin
was positively associated with the rate of DBP variation in
the mildly impaired renal function group during the awake
(β = .568, P < .05) and 24-hour (β = .570, P < .05)
periods. No associations were found for urinary albumin and
BPV or BP variation parameters in the normal renal function
group.

3.5. Plasma and Urinary NOx. Plasma NOx (pNOx), urinary
NOx (uNOx), and the uNOx/pNOx ratio were analyzed
to investigate the potential role of NO as an underlying
mechanism linking renal function to BP fluctuations. pNOx
levels were significantly higher in the mildly impaired renal
function group (normal: 19.2 ± 2.8 versus mildly impaired:
27.2 ± 3.6 μmol/L; P < .05). There were no statistically
significant diﬀerences between the two groups for uNOx
(normal: 620.3 ± 79.7 versus mildly impaired: 753.5 ±
153.4 μmol/gCr) and the uNOx/pNOx ratio (normal: 39.5 ±
5.6 versus mildly impaired: 28.4 ± 5.8).
In univariate regression analyses predicting GFR, both
pNOx (β = −.495, P < .05) and the uNOx/pNOx ratio
(β = .457, P < .01) were significantly associated with
GFR (Figure 3).When inserted into a multivariate regression
model that included age, BMI, 24-hour SBP, and 24-hour
DBP, pNOx remained a significant of predictor of GFR (β =
−.372; P < .05). The uNOx/pNOx ratio also remained a
significant predictor of GFR (β = −.393; P < .05) when
inserted into a multivariate regression model that included
age and BMI, but did not remain a significant predictor when
24-hour SBP and 24-hour DBP were added to the model. For
univariate regression analyses predicting urinary albumin,
there was a significant negative association between uNOx
and urinary albumin (β = −.497; P < .01) that remained
significant when inserted into a multivariate regression
that included age, BMI, 24-hour SBP, and 24-hour SBP
(β = −.625; P < .01).
In order to determine the relationship between a
potential BP-buﬀering mechanism (NO) and fluctuations in
BP, univariate regression analyses predicting BPV and BP
variation parameters were conducted. A significant negative
association existed between pNOx and 24-hour diastolic
BPV (β = −.356, P < .05). All remaining renal and
ABPM variables showed no significant associations with
either pNOx, uNOx, or the uNOx/pNOx ratio in the entire
study group or in renal function subgroups.
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Table 3: Univariate regression analyses predicting GFR.
Variable
Age (years)
Male Gender
Med. Taper
BMI (kg/m2)
Fat Free Mass (kg)
Fat Mass (kg)
Total Cholesterol (mg/dL)
LDL Cholesterol (mg/dL)
HDL Cholesterol (mg/dL)
Triglycerides (mg/dL)
Glucose (mg/dL)
Awake SBP (mmHg)
Sleep SBP (mmHg)
24-hr SBP (mmHg)
Awake DBP (mmHg)
Sleep DBP (mmHg)
24-hr DBP (mmHg)
Awake MAP (mmHg)
Sleep MAP (mmHg)
24-hr MAP (mmHg)
Awake Systolic BPV (mmHg)
Sleep Systolic BPV (mmHg)
24-hr Systolic BPV (mmHg)
Awake Rate of SBP Variation (mmHg/min)
Sleep Rate of SBP Variation (mmHg/min)
24-hr Rate of SBP Variation (mmHg/min)
Awake Diastolic BPV (mmHg)
Sleep Diastolic BPV (mmHg)
24-hr Diastolic BPV (mmHg)
Awake Rate of DBP Variation (mmHg/min)
Sleep Rate of DBP Variation (mmHg/min)
24-hr Rate of DBP Variation (mmHg/min)
Awake MAPV (mmHg)
Sleep MAPV (mmHg)
24-hr MAPV (mmHg)
Awake Rate of MAP Variation (mmHg/min)
Sleep Rate of MAP Variation (mmHg/min)
24-hr Rate of MAP Variation (mmHg/min)

β
−0.276

0.005
−0.282
0.179
0.091
0.124
−0.306
−0.152
−0.185
−0.252
0.068
−0.038
−0.005
0.023
0.131
0.154
0.213
0.052
0.120
0.145
0.133
0.169
0.199
0.114
0.135
0.153
0.549
0.240
0.524
0.573
0.228
0.626
0.357
0.164
0.431
0.342
0.163
0.383

P Value
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
<.001
NS
.001
<.001
NS
<.001
.033
NS
.008
.041
NS
.014

BMI, body mass index; BPV, blood pressure variability; DBP, diastolic blood
pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; MAP, mean arterial pressure, MAPV, mean
arterial pressure variability; NS, nonsignificant; SBP, systolic blood pressure.

4. Discussion
In the present study, we used two indices of BPV to
investigate the relationship between renal function and BP
variation: the ARV index, which accounts for the order in
which BP measurements are obtained, and the time rate
of variation, which accounts for the order in which BP
measurements are obtained, as well as the time between
successive readings. Our results show that normotensive and

Table 4: Multivariate regression analyses predicting GFR.
Variable
Awake Diastolic BPV
(mmHg)
24-Hr Diastolic BPV
(mmHg)
Awake Rate of DBP
Variation (mmHg/min)
24-Hr Rate of DBP
Variation (mmHg/min)
Awake MAPV (mmHg)
24-Hr MAPV (mmHg)
Awake Rate of MAP
Variation (mmHg/min)
24-Hr Rate of MAP
Variation (mmHg/min)

β

P Value

0.553

.003

0.595

.001

0.538

.002

0.621

.001

0.284
0.308

NS
NS

0.221

NS

0.259

NS

The listed variables were entered separately into a multivariate regression
model containing age, BMI, SBP, and DBP. BPV, blood pressure variability;
DBP, diastolic blood pressure; GFR, glomerular filtration rate; MAP, mean
arterial pressure; MAPV, mean arterial pressure variability.

pre-hypertensive African Americans with mildly impaired
renal function exhibit lower diastolic BPV and a lower rate
of variation in DBP when compared to African Americans
with normal renal function. Moreover, diastolic BPV and
the rate of variation in DBP were identified as independent
determinants of renal function, as both indices of DBP
variation positively correlated with GFR in this cohort of
African Americans.
Our findings conflict with previous studies in diseased
populations, as it has been more often shown that greater
BP variation is associated with poorer health outcomes
in patients with essential hypertension or chronic kidney
disease (CKD). Most recently, Manios et al. found that
systolic and diastolic BPV and the 24-hour rate of SBP
variation were significantly greater in hypertensive patients
with a GFR less than 60 mL/min per 1.73 m2 when compared
to hypertensive patients with a GFR greater than 60 mL/min
per 1.73 m2 [9]. However, few studies have investigated BP
variations in populations without overt clinical disease as the
majority of studies investigating BPV have been conducted
in hypertensive populations. Given that hypertensive BP
loads are directly associated with TOD, and considering that
hypertension may be a cause or consequence of baroreceptor
and/or endothelial dysfunction; the observed associations
between BPV and TOD in these populations could be a result
of the eﬀects of a hypertensive BP load on both organs and
BP-buﬀering mechanisms. Thus, our disparate findings may
simply be representative of subclinical populations in which
some of the BP-buﬀering mechanisms are still intact, and
could suggest that changes in BP regulation mechanisms,
resulting in wider BP fluctuations, may occur during the
progression of both CKD and hypertension from early,
subclincal disease states. This hypothesis is corroborated by
our finding that urinary albumin excretion was positively
associated with the rate of DBP variation in the mildly
impaired renal function group, while no such association
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was found in the normal renal function group. However, it
should be acknowledged that the cross-sectional design of
the present study cannot determine whether changes in BP
variation promoted CKD or vice versa.
It has been proposed that NO may serve as a BP-buﬀering
mechanism that regulates fluctuations in BP level [10].
Several animal studies have shown that BPV increases with
blockade or knockout of endothelial nitric oxide synthase
[17, 18], however, to the best of our knowledge, this is
the first study to demonstrate a relationship between NO
and BPV obtained from ABPM in humans, as a negative
association between diastolic BPV and pNOx levels was
found. Interestingly, the mildly impaired renal function
group exhibited greater pNOx levels than the normal renal
function group. Moreover, when GFR was analyzed as a
continuous variable, pNOx negatively correlated with GFR
and was identified as an independent determinant of renal
function. NO plays a major role in renal perfusion and
glomerular filtration [19]; therefore, the elevation in pNOx
with declining GFR observed in the present study may serve
as a compensatory mechanism to maintain blood flow to the
kidneys in an eﬀort to preserve GFR. This is the first study
to compare NOx levels in African Americans with normal or
mildly impaired renal function; therefore, our findings need
to be confirmed; however, in support of NO serving in a
compensatory capacity are several animal studies which have
also observed a paradoxical increase in NO with declining
renal function [20–22]. In keeping with the hypothesis of NO
as a BP-buﬀering mechanism, it therefore seems plausible
that the lower BP variation observed in the mildly impaired
renal function group may be the result of higher levels of NO
production.
It is interesting to note that higher pNOx levels were
associated with lower GFR, while no such association was
observed between uNOx levels and GFR. Because 60%–
73% of pNOx is excreted renally [23, 24], we also calculated the uNOx/pNOx ratio in order assess uNOx derived
from the kidneys after accounting for basal pNOx levels.
Our findings showed that a lower uNOx/pNOx ratio was
associated with a lower GFR, which could suggest that NO
production in the kidney is attenuated with declining renal
function. In accordance with these findings, we observed that
lower uNOx was associated with increased urinary albumin
excretion. It has been previously shown that NO production
in localized areas of the kidney, including the cortex and
outer and inner medulla, is important in the regulation
of renal hemodynamics [25]. Moreover, it has been well
reported in both clinical and animal studies that deficiencies
in NO are associated with kidney damage and/or chronic
kidney disease progression [26]. As such, diminished NO
production/bioavailability in the kidney could be underlying
the finding of reduced BPV in subjects with mildly impaired
renal function.
To the best of our knowledge, this is the first study to
investigate BP variations in relationship to renal function
in a cohort of African Americans. Therefore, our finding
that diastolic BPV and MAPV, but not systolic BPV, were
strongly associated with renal function may be the result
of underlying race specific contributions to BP regulation.
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Increased peripheral vascular resistance caused by arterial
vasoconstriction is the key determinant of DBP, particularly
before 50–60 years of age. In previous studies, when the
hemodynamic mechanisms that underlie the BP response
were assessed to determine their influence on BP variations from ABPM measurements in diﬀerent racial groups,
systemic vascular resistance was found to play a more
prominent role in the regulation of BP in African Africans
when compared to whites. In contrast, cardiac output was
a prominent contributor to ABPM measurements only in
whites and not in African Americans [27]. Moreover, when
the hemodynamic responses were compared among racial
group after three separate laboratory stressors, the pressor
responses in African Americans were found to be mediated
to a greater extent by vascular tone when compared to
whites [28]. In keeping with the role of peripheral vascular
resistance as the key determinant of DBP, it therefore may be
reasonable to hypothesize that the strong associations found
for the measures of DBP and MAP variations, and not for
the SBP variations in the present study, may be attributed to
the greater contribution of systemic vascular resistance to BP
regulation in African Americans as they are exposed to daily
stressors in their natural environment.
Several limitations of this study must be noted when
interpreting these findings. First, our sample size is small.
However, because of our extensive exclusion criteria, many
confounding variables that may influence renal function
were well controlled for. Second, the low frequency of BP
measurements with ABPM limits the capacity to optimally
assess BP variation. Conversely, the use of ABPM permits
the assessment of the variation of BP in a participant’s
natural environment where they are exposed to the various
psychological and environmental stressors which influence
their BP on a daily basis. Third, the reproducibility of
BP variation may be poor due to the large influence of
daily activity on BP variations. Finally, our cross-sectional
study design allowed us to assess the relationship between
renal function and BPV, but not to assess cause-eﬀect
relationships. Prospective studies are needed to determine
whether the progression from the early stages of CKD to
end-stage renal disease confers changes in the physiological
mechanisms that regulate BPV.
In conclusion, our study provides novel information
on the relationship between BPV and renal function by
assessing their relationship for the first time in a group of
normotensive and pre-hypertensive African Americans with
normal or mildly impaired renal function. Our findings
suggest that both the magnitude and rate of diastolic BPV
are reduced in African Americans with mildly impaired renal
function, which may in part be the result of a compensatory
mechanism in the early stages of hypertension and kidney
disease, whereby NO levels in the blood are elevated. These
results conflict with previous studies in diseased populations
and diﬀerent races as the relationship between BPV and
renal function is reversed in patients with more advanced
renal dysfunction and higher BP levels. Future studies should
investigate whether changes in BP regulation mechanisms,
resulting in wider BP fluctuations, may be involved in
the progression of both renal disease and hypertension,
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and whether these changes could explain the accelerated
progression of CKD found in African Americans.
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and T. Sulbarán, “A reliable index for the prognostic significance of blood pressure variability,” Journal of Hypertension,
vol. 23, no. 3, pp. 505–511, 2005.
[14] S. D. Pierdomenico, M. Di Nicola, A. L. Esposito et al., “Prognostic value of diﬀerent indices of blood pressure variability in
hypertensive patients,” American Journal of Hypertension, vol.
22, no. 8, pp. 842–847, 2009.
[15] N. A. Zakopoulos, G. Tsivgoulis, G. Barlas et al., “Time rate of
blood pressure variation is associated with increased common
carotid artery intima-media thickness,” Hypertension, vol. 45,
no. 4, pp. 505–512, 2005.
[16] D. L. Feairheller, K. M. Sturgeon, K. M. Diaz et al., “Prehypertensive African-American women have preserved nitric oxide
and renal function but high cardiovascular risk,” Kidney and
Blood Pressure Research, vol. 33, no. 4, pp. 282–290, 2010.
[17] H. M. Stauss, B. Nafz, R. Mrowka, and P. B. Persson,
“Blood pressure control in eNOS knock-out mice: comparison
with other species under NO blockade,” Acta Physiologica
Scandinavica, vol. 168, no. 1, pp. 155–160, 2000.
[18] B. N. van Vliet, L. L. Chafe, and J. P. Montani, “Characteristics
of 24 h telemetered blood pressure in eNOS-knockout and
C57Bl/6J control mice,” Journal of Physiology, vol. 549, no. 1,
pp. 313–325, 2003.
[19] C. Baylis and C. Qiu, “Importance of nitric oxide in the control
of renal hemodynamics,” Kidney International, vol. 49, no. 6,
pp. 1727–1731, 1996.
[20] N. Bank, “Renal hemodynamic consequences of hyperlipidemia,” Mineral and Electrolyte Metabolism, vol. 19, no. 3, pp.
165–172, 1993.
[21] R. L. Minor, P. R. Myers, R. Guerra, J. N. Bates, and D. G.
Harrison, “Diet-induced atherosclerosis increases the release
of nitrogen oxides from rabbit aorta,” Journal of Clinical
Investigation, vol. 86, no. 6, pp. 2109–2116, 1990.
[22] M. M. Rahman, Z. Varghese, and J. F. Moorhead, “Paradoxical
increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased
activity of nitric oxide,” Nephrology Dialysis Transplantation,
vol. 16, no. 2, pp. 262–268, 2001.
[23] L. C. Green, K. Ruiz de Luzuriaga, and D. A. Wagner, “Nitrate
biosynthesis in man,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 78, no. 12 II, pp.
7764–7768, 1981.
[24] U. N. Westfelt, G. Benthin, S. Lundin, O. Stenqvist, and A.
Wennmalm, “Conversion of inhaled nitric oxide to nitrate
in man,” British Journal of Pharmacology, vol. 114, no. 8, pp.
1621–1624, 1995.
[25] B. C. Kone and C. Baylis, “Biosynthesis and homeostatic roles
of nitric oxide in the normal kidney,” American Journal of
Physiology, vol. 272, no. 5, pp. F561–F578, 1997.
[26] C. Baylis, “Nitric oxide deficiency in chronic kidney disease,”
American Journal of Physiology, vol. 294, no. 1, pp. F1–F9,
2008.
[27] A. Sherwood, J. W. Hughes, and J. McFetridge, “Ethnic
diﬀerences in the hemodynamic mechanisms of ambulatory
blood pressure regulation,” American Journal of Hypertension,
vol. 16, no. 4, pp. 270–273, 2003.
[28] A. Sherwood, C. W. May, W. C. Siegel, and J. A. Blumenthal,
“Ethnic diﬀerences in hemodynamic responses to stress in
hypertensive men and women,” American Journal of Hypertension, vol. 8, no. 6, pp. 552–557, 1995.

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Diabetes Research
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com

Disease Markers

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
http://www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Oncology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

AIDS

Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com

Research and Treatment
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

